ABSTRACT: Intestinal flora is a key factor in insulin resistance and contribute to the development of polycystic ovary syndrome and ameliorates glucose metabolism via activation of intestinal farnesoid X receptor
Project description:Intestinal flora is a key factor in insulin resistance and contribute to the development of polycystic ovary syndrome and ameliorates glucose metabolism via activation of intestinal farnesoid X receptor (Human)
Project description:Intestinal flora is a key factor in insulin resistance and contribute to the development of polycystic ovary syndrome and ameliorates glucose metabolism via activation of intestinal farnesoid X receptor (Mice)
Project description:Intestinal flora is a key factor in insulin resistance and contribute to the development of polycystic ovary syndrome and ameliorates glucose metabolism via activation of intestinal farnesoid X receptor
Project description:Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. It has become increasingly evident that insulin resistance plays a significant role both as a cause and result of the syndrome. In an effort to investigate further the observed insulin resistance in the ovarian tissue of women with PCOS, we conducted array-based, global miRNA profiling.
Project description:This experiment was designed to study if there are differences in gene expression in the adipose tissue of women affected by polycystic ovary syndrome (PCOS) compared to non-hyperandrogenic women. PCOS is the most common endocrinopathy in women of reproductive age, and is characterized by hyperandrogenism and chronic anovulation. This disease is frequently associated with obesity, insulin resistance, and defects in insulin secretion, predisposing these women to type 2 diabetes, atherosclerosis, and cardiovascular disease. We have applied high-density oligonucleotide arrays to omental adipose tissue samples obtained from eight morbidly obese PCOS patients and seven morbidly obese non-PCOS women at the time of bariatric surgery. Keywords: Disease state analysis
Project description:Polycystic ovary syndrome (PCOS) is a highly prevalent disorder, affecting one in eight women across the world. It is commonly accompanied by metabolic syndrome, including obesity, insulin resistance, impaired glucose tolerance and dyslipidemia. Activation of the hypoxia-inducible factor (HIF) pathway is known to alleviate metabolic defects and counteract obesity. Hence, this study utilized a preclinical PCOS mouse model to investigate the effects of chemically induced HIF activation on the metabolic traits of the syndrome.
Project description:To reveal mRNAs expression differences in cumulus cells between polycystic ovary syndrome (PCOS) and non-PCOS women. mRNAs expression profile of the cumulus cell samples with PCOS and non-PCOS were determined by Illumina Novaseq 6000.
Project description:To reveal microRNAs expression differences in cumulus cells between polycystic ovary syndrome (PCOS) and non-PCOS women. miRNAs expression profile of the cumulus cell samples with PCOS and non-PCOS were determined by Affymetrix miRNA 2.0.
Project description:As a heterogeneous reproductive disorder with unclear etiopathogenesis, polycystic ovary syndrome (PCOS) can be caused by genetic, diet, and environmental factors. Bisphenol A (BPA), a global environmental contaminant, can induce PCOS and NAFLD due to direct exposure; however, whether these phenotypes persist in future unexposed generations is not currently understood. We observed genes abnormally expressed in the ovary of BPA lineage, similar to human PCOS patients. IPA analyses revealed activation of the cancerous pathway, arginine-proline metabolism, insulin signaling, AMPK, and HOTAIR regulatory pathways, as well as upstream regulators esr1 and tgf β.
Project description:To reveal microRNAs expression differences in cumulus cells between polycystic ovary syndrome (PCOS) and non-PCOS women. miRNAs expression profile of the cumulus cell samples with PCOS and non-PCOS were determined by Affymetrix miRNA 2.0. Six pooled RNAs from CC samples (three PCOS and three non-PCOS pooled RNAs) were separately analyzed on 6 GeneChip miRNA 2.0 Array (miRBase V15)
